谁给我翻译一下有关药品方面的英文文章, 翻译好的话再加50分

谁给我翻译一下有关药品方面的英文文章, 翻译好的话再加50分
Original Article
Acta Pharmacologica Sinica 31, 746-752 (June 2010) | doi:10.1038/aps.2010.50
Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
Yun Fan, Neng-ming Lin, Sheng-lin Ma, Lü-hong Luo, Luo Fang, Zhi-yu Huang, Hai-feng Yu and Feng-qin Wu
Abstract
Aim:
To investigate the pharmacodynamics and pharmacokinetics of gemcitabine (dFdC) administered on d 1 and 5 plus cisplatin administered on d 1 in chemonaive patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
Methods:
In each combination cycle, gemcitabine was administered at a dose of 1250 mg/m2 as a 30 min intravenous (iv) infusion on d 1 and 5 followed by cisplatin at a dose of 75 mg/m2 as a 3 h iv infusion on d 1 every 3 weeks. There was an interval of 1 h between the two infusions. Clinical response and toxicity of the regimen were observed. Furthermore, the plasma concentrations of gemcitabine (dFdC) and its metabolite (dFdU) at different time points were detected during the first cycle of infusion. Pharmacokinetic software (PKS) was used to estimate the pharmacokinetic parameters of gemcitabine and its metabolite dFdU.
Results:
A total of 28 patients was enrolled in the study. The median age was 54 years (range 27–75 years), and most patients were in good clinical condition. Twenty-seven patients received two or more treatment cycles. The overall clinical response rate was 33.3%. The median overall survival time was 13 months. The estimated median time to tumor progression (TTP) was 6.2 months, and the 1-year survival rate was 55.6%. Toxicities were tolerated. The main toxicity was myelosuppression; 35.7% of patients had grade 3/4 hematologic toxicities and 28.6% had grade 3/4 non-hematologic toxicities, which were commonly gastrointestinal responses. The pharmacokinetic parameters of dFdC and dFdU were not different between pre- and post-administration of gemcitabine on d 1 and 5. dFdU was minimal (0.729±0.637 μg/mL) before gemcitabine was infused on d 5, and gemcitabine was not present.
Conclusion:
The regimen is active and well tolerated in chemonaive patients with advanced NSCLC. After gemcitabine was administered on d 1 and 5, the pharmacokinetic parameters of dFdC and dFdU showed no difference from those before the infusion, and dFdU was minimal before gemcitabine was administered on d 5.

研究论文
中国药理学报2010年6月31期 746-752页 【数字对象唯一标识符】：10.1038/aps.2010.50
吉西他滨联合顺铂治疗Ⅱ期非小细胞肺癌的临床研究
范云,李能明,马胜林,罗吕红,罗芳,黄志宇,于海峰,吴凤琴
摘要
目的：对未接受过化疗的III期和IV期非小细胞肺癌（NSCLC）患者,静脉注射吉西他滨,d1、d5,顺铂 d1,以研究吉西他滨（dFdC）的药效学药和药代动力学.
方法：
一个联合治疗周期,吉西他滨1250 mg/m2,静脉输液30 min,d1、d5,每三周静脉输液一次顺铂75mg/m2,d1.两次注射间隔1hr.观察该方案的毒性反应.此外,第一次输液周期中监测不同时期的吉西他滨（dFdC）及其代谢产物（dFdU）的血药浓度.使用药代动力学软件（PKS）评价吉西他滨及其代谢产物（dFdU）药代动力学参数.
结果：
共有28名患者参与此项研究,平均年龄54岁（介于27~75岁之间）,大多数病人的临床表现良好.27名患者接受了2个或以上的治疗周期.临床总有效率为33.3%.中位生存期13个月.估算的肿瘤进展时间(TTP)中位天数为6.2个月,1年生存率为55.6%.毒性反应总的较轻.主要毒性为骨髓抑制；35.7%的病人出现3/4度血液学毒性,而28.6%的病人出现3/4度非血液学毒性——常见的胃肠道反应.吉西他滨及其代谢产物（dFdU）药代动力学参数在注射吉西他滨d1、d5前后无差异.在注入吉西他滨d5前,dFdU（2,2'—双氟脱氧胞嘧啶核苷）的最低浓度为0.729±0.637 μg/mL,而吉西他滨未检测到.
结论：
该方案是治疗未接受过化疗的非小细胞肺癌（NSCLC）晚期患者的有效方案,总体临床耐受性良好.在静脉滴入吉西他滨,d1、d5后,吉西他滨及其代谢产物（dFdU）药代动力学参数较之前无差异,而在注入吉西他滨d5前,dFdU（2,2'—双氟脱氧胞嘧啶核苷）浓度最低.